Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, briefly discusses the importance of genomic testing in myeloproliferative neoplasms (MPNs), highlighting the benefit of using next-generation sequencing (NGS) methods where possible, and the value of using genomic information to guide treatment decisions. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.